Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison

Michael Curtis¹, Justin Berk², Sarah Larney³, Josiah D Rich⁴, Mark Stoové⁵

Affiliations

¹ Behaviours and Health Risks Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Monash Addition Research Centre, Monash University, Melbourne, VIC, Australia. Electronic address: michael.curtis@burnet.edu.au.
² Warren Alpert Medical School, Brown University, Providence, RI, USA; Rhode Island Department of Corrections, Cranston, RI, USA.
³ Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Department of Family Medicine and Emergency Medicine, Université de Montréal, Quebec, Canada; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.
⁴ Warren Alpert Medical School, Brown University, Providence, RI, USA; Department of Epidemiology, Brown University, Providence, RI, USA; The Center for Health + Justice Transformation, The Miriam Hospital, Providence, RI, USA.
⁵ Behaviours and Health Risks Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

PMID: 34998045
PMCID: PMC8810681
DOI: 10.1016/j.drugpo.2021.103572

Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison

Michael Curtis et al. Int J Drug Policy. 2022 Feb.

. 2022 Feb:100:103572.

doi: 10.1016/j.drugpo.2021.103572. Epub 2022 Jan 5.

Authors

Michael Curtis¹, Justin Berk², Sarah Larney³, Josiah D Rich⁴, Mark Stoové⁵

Affiliations

¹ Behaviours and Health Risks Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Monash Addition Research Centre, Monash University, Melbourne, VIC, Australia. Electronic address: michael.curtis@burnet.edu.au.
² Warren Alpert Medical School, Brown University, Providence, RI, USA; Rhode Island Department of Corrections, Cranston, RI, USA.
³ Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Department of Family Medicine and Emergency Medicine, Université de Montréal, Quebec, Canada; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.
⁴ Warren Alpert Medical School, Brown University, Providence, RI, USA; Department of Epidemiology, Brown University, Providence, RI, USA; The Center for Health + Justice Transformation, The Miriam Hospital, Providence, RI, USA.
⁵ Behaviours and Health Risks Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

PMID: 34998045
PMCID: PMC8810681
DOI: 10.1016/j.drugpo.2021.103572

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest MS has received investigator-initiated funding from Gilead Sciences, AbbVie and Bristol Myers Squibb, and consultant fees from Gilead Sciences for activities unrelated to this work. SL has received untied investigator driven funding from Indivior unrelated to this work. The other authors have no disclosures.

Cited by

Opioid-related harms and experiences of care among people in justice settings in New South Wales, Australia: evidence from the National Ambulance Surveillance System.
Beard N, McGrath M, Lai HMX, Wilson J, Hew A, Labiano AM, Lubman DI, Ogeil RP. Beard N, et al. Harm Reduct J. 2025 Jan 15;22(1):8. doi: 10.1186/s12954-025-01154-7. Harm Reduct J. 2025. PMID: 39815283 Free PMC article.
Medication for opioid use disorder service delivery in carceral facilities: update and summary report.
Berk J, South AM, Martin M, James ME, Miller C, Haber L, Rich J. Berk J, et al. Health Justice. 2025 Feb 1;13(1):8. doi: 10.1186/s40352-025-00317-9. Health Justice. 2025. PMID: 39891797 Free PMC article. Review.
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Stopka TJ, et al. Int J Drug Policy. 2022 Dec;110:103803. doi: 10.1016/j.drugpo.2022.103803. Epub 2022 Aug 11. Int J Drug Policy. 2022. PMID: 35965159 Free PMC article.

References

1. Bird SM, Fischbacher CM, Graham L, & Fraser A (2015). Impact of opioid substitution therapy for Scotland’s prisoners on drug-related deaths soon after prisoner release. Addiction, 110(10), 1617–1624. 10.1111/add.12969 - DOI - PMC - PubMed
1. Bucerius SM, & Haggerty KD (2019). Fentanyl behind bars: The implications of synthetic opiates for prisoners and correctional officers. International Journal of Drug Policy, 71, 133–138. 10.1016/j.drugpo.2019.05.018 - DOI - PubMed
1. Carlson RG, Daniulaityte R, Silverstein SM, Nahhas RW, & Martins SS (2020). Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? International Journal of Drug Policy, 79, 102722. 10.1016/j.drugpo.2020.102722 - DOI - PMC - PubMed
1. Clark N, Dolan K, & Farabee D (2017). Public health alternatives to incarceration for drug offenders. Eastern Mediterranean Health Journal, 23(3), 222–230. 10.26719/2017.23.3.222 - DOI - PubMed
1. Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, … Burns L (2014). The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction, 109(8), 1306–1317. 10.1111/add.12536 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison

Affiliations

Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical